Tovaxin for multiple sclerosis

Bibliography

• Wucherpfenning K, Stromiger J. Molecular mimicry in T cell-mediated autoimmunity: viral peptides active human T cell clones specific to myelin basic protein. Cell 1995;80:695-705
   PubMed Web of Science ®Google Scholar
• Bitsch A, Schuchardt A, Bunkewski S, Acute axonal injury in multiple sclerosis: correlation with demyelination and inflammation. Brain 2000;123:1174-83
   PubMed Web of Science ®Google Scholar
• Stinissen P, Raus J, Zhang J. Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Crit Rev Immunol 1997;17:33-75
   PubMed Web of Science ®Google Scholar
• Marks DJ, Segal AW. Innate immunicity in inflammatory bowel disease: a disease hypothesis. J Pathol 2008;214:260-6
   PubMed Web of Science ®Google Scholar
• Hauqe MA, Kimoto M, Inada S, Autoreactive CD4–CD8–alpha,beta T cells to vaccinate adjuvant arthritis. Immunology 1998;94:536-42
   PubMed Web of Science ®Google Scholar
• Luchinetti CF, Bruck W, Rodriguez M, Lassmann H. Multiple sclerosis: lessons from neuropathology. Semin Neurol 1998;18:337-49
   PubMed Web of Science ®Google Scholar
• Kasper LH, Shoemaker J. The healthy immune system vs the MS immune system. Neurology 2010;74:52-8
   Web of Science ®Google Scholar
• Hauser SL, Ocksenberg JR. The neurology of multiple sclerosis: Genes, inflammation and neurodegeneration. Neuron 2006;52:61-76
   PubMed Web of Science ®Google Scholar
• De Jager P, Baecher-Allan C, Maier ML, The role of the CD58 locus in multiple sclerosis. PNAS 2009;106:5264-9
   PubMed Web of Science ®Google Scholar
• Garren H. A DNA vaccine for multiple sclerosis. Expert Opin Biol Ther 2008;8:1539-50
   PubMed Web of Science ®Google Scholar
• Garren H, Robinson WH, Krasulova E, BHT-3009 Study Group. Phase II trial of a DNA encoding myelin basic protein for multiple sclerosis. Ann Neurol 2008;63:611-20
   PubMed Web of Science ®Google Scholar
• Stein D, Drusano GL. Modeling of the change in CD4 lymphocyte counts in patients before and after administration of the human immunodeficiency virus protease inhibitor Indinavir. Antimicrob Agents Chemother 1997;41:449-53
   PubMed Web of Science ®Google Scholar
• Zang CQY, Hong J, Rivera V, Preferential recognition of TCR hypervariable regions by human anti-idiotypic T cells induced by T cell vaccination. J Immunol 2000;164:4011-15
   PubMed Web of Science ®Google Scholar
• Medaer R, Stinissen P, Truyen L, Depletion of myelin basic protein autoreactive T-cells by T-cell vaccination. Clinical trial in multiple sclerosis. Lancet 1995;346:807-8
   PubMed Web of Science ®Google Scholar
• Hong J, Zang CQY, Tejada-Simon MV, Reactivity and regulatory properties of human anti-idiopypic antibodies induced by T cell vaccination. J Immnunol 2000;165:6858-64
   PubMed Web of Science ®Google Scholar
• Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with T lymphocytes line cells reactive against myelin basic protein. Nature 1981;292:60-9
   PubMed Web of Science ®Google Scholar
• Hafler D, Cohen IR, Benjamine D, Weiner HL. T-cell vaccination in multiple sclerosis: a preliminary report. Clin Immunol Immunopath 1992;140:112-22
   Google Scholar
• Cohen IR. Natural Id-anti-Id networks and the immunological homunculus. In: Atlan H, Cohen IR (eds). Theories of Immune Networks. New York: Springer. Berlin, Heidelberg, 1989:6-12
   Google Scholar
• Kozovska M, Zang CQY, Aebischer I, T cell recognition motifs of an immunodominant peptide of myelin basic protein in patients with multiple sclerosis: structural requirements and clinical implications. Eur J Immunol 1998;28:1894-901
   PubMed Web of Science ®Google Scholar
• Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991;87:949-54
   PubMed Web of Science ®Google Scholar
• Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-72
   PubMed Web of Science ®Google Scholar
• Ben-Nun, Wekerle H, Cohen IR. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 1981;11:195-204
   PubMed Web of Science ®Google Scholar
• Lider O, Reshef T, Ben-Nun A, Cohen IR. Anti-idiotypic-network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science 1988;238:181-3
   Web of Science ®Google Scholar
• Chan MA, Stein LD, Dosch HM, Sigal NH. Heterogeneity of EBV-transformable human B lymphocyte populations. J Immunol 1986;136:106-12
   PubMed Web of Science ®Google Scholar
• Vandevyver C, Martens N, van de Elsen P, Clonal expansion of myelin basic protein-reactive T cells in patients with multiple sclerosis: restricted T cell receptor V gene rearrangements and CDR3 sequence. Eur J Immunol 1995;25:958-68
   PubMed Web of Science ®Google Scholar
• Baylor College of Medicine, Institutional Review Board. Protocol H-9857. “An Open-Label, Dose Escalation Study of T-Cell Vaccination in Multiple Sclerosis” (FDA Protocol #2000-03)
   Google Scholar
• Zang CQY, Hong J, Tejada-Simon MV. Th2 immune regulation induced by T cell vaccination in patients with multiple sclerosis. Eur J Immunol 2000;30:908-13
   PubMed Web of Science ®Google Scholar
• Wucherpfenning KW, Zhang J, Witek C, Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 1994;152:5581-92
   PubMed Web of Science ®Google Scholar
• Correale J, Lund B, McMillan M, T-cell vaccination in secondary progressive Multiple Sclerosis. J Neuroimmunol 2000;107:130-9
   PubMed Web of Science ®Google Scholar
• Zhang J, Rivera VM, Sufang L, Vaccination with myelin-reactive T cells; results of a clinical trial in patients with multiple sclerosis. Neurology 2000;54(Suppl 3):A23 [Abstract S11.203]
   Google Scholar
• Zhang J, Rivera VM, Tejada-Simon MV, T cell vaccination in multiple sclerosis: results of a preliminary study. J Neurol 2002;492:212-18
   Web of Science ®Google Scholar
• Tovaxin. The Woodlands, TX: Opexa Therapeutics, Inc 2010. Available from: http://www.opexatherapeutics.com/?page=tovaxin&section=tovaxin [Last accessed 2 May 2011]
   Google Scholar
• Loftus B, Newsome B, Montgomery M, Autologous attenuated T cell vaccine (Tovaxin)dose escalation in multiple sclerosis relapsing-remitting and secondary progressive in patients not responsive to approved immunomodulatory therapies. Clin Immunol 2009;13(2):202-15
   Web of Science ®Google Scholar
• Fox E. TERMS (Tovaxin® for Early Relapsing MS) phase2b placebo-controlled trial of autologous T-cell vaccination in patients with clinically isolated syndrome or relapsing remitting multiple sclerosis. Montreal World Congress on Treatment and Research in Multiple Sclerosis, 2008. Multiple Sclerosis 2008;14(Suppl 1):56
   Google Scholar
• Markowitz C, Wynn D, Fox E, Autologous T-cell immunotherapy in treatment-naive patients with active relpasing-remitting multiple sclerosis. Neurology 2011;76: Number 9: PO7-192 (Suppl 4) (Abstract)
   Web of Science ®Google Scholar